{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:14:32Z","timestamp":1788498872649,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Wuhan Science and Technology Achievement Transformation Project","award":["2024030803010193"],"award-info":[{"award-number":["2024030803010193"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"DOI":"10.1007\/s12185-026-04273-4","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:22:51Z","timestamp":1788495771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Belumosudil for acute GVHD after allogeneic hematopoietic stem cell transplantation: a retrospective case series"],"prefix":"10.1007","author":[{"given":"Yaogong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yize","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"1","key":"4273_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Primers. 2023;9(1):27.","journal-title":"Nat Rev Dis Primers"},{"issue":"17","key":"4273_CR2","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.20.00619","volume":"39","author":"R Reshef","year":"2021","unstructured":"Reshef R, Saber W, Bolanos-Meade J, Chen G, Chen YB, Ho VT, et al. Acute GVHD diagnosis and adjudication in a multicenter trial: a report from the BMT CTN 1202 biorepository study. J Clin Oncol. 2021;39(17):1878\u201387.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4273_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3324\/haematol.2020.265769","volume":"107","author":"HT Greinix","year":"2022","unstructured":"Greinix HT, Eikema DJ, Koster L, Penack O, Yakoub-Agha I, Montoto S, et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica. 2022;107(5):1054\u201363.","journal-title":"Haematologica"},{"issue":"9","key":"4273_CR4","first-page":"1998","volume":"110","author":"HT Kim","year":"2025","unstructured":"Kim HT, Soiffer RJ, Cutler C, Koreth J, Nikiforow S, Shapiro RM, et al. Reduced incidence of relapse and graft-versus-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Haematologica. 2025;110(9):1998\u20132008.","journal-title":"Haematologica"},{"issue":"9","key":"4273_CR5","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ajh.27383","volume":"99","author":"A Nagler","year":"2024","unstructured":"Nagler A, Ngoya M, Galimard JE, Labopin M, Blau IW, Kroger N, et al. Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: a study on behalf of the Acute leukemia working party of the European society for blood and marrow transplantation. Am J Hematol. 2024;99(9):1732\u201345.","journal-title":"Am J Hematol"},{"issue":"7","key":"4273_CR6","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow transplant. 2021;56(7):1651\u201364.","journal-title":"Bone Marrow transplant"},{"issue":"2","key":"4273_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41409-024-02459-0","volume":"60","author":"JR Passweg","year":"2025","unstructured":"Passweg JR, Baldomero H, Alexander T, Angelucci E, Averbuch D, Bazarbachi A, et al. Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT. Bone Marrow Transplant. 2025;60(2):227\u201336.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"4273_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","volume":"107","author":"D Niederwieser","year":"2022","unstructured":"Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045\u201353.","journal-title":"Haematologica"},{"issue":"2","key":"4273_CR9","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation. Lancet Haematol. 2024;11(2):e147\u201359.","journal-title":"Lancet Haematol"},{"issue":"8","key":"4273_CR10","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American society of blood and marrow transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150\u201363.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 3","key":"4273_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/ajh.27592","volume":"100","author":"P Smallbone","year":"2025","unstructured":"Smallbone P, Mehta RS, Alousi A. Steroid refractory acute GVHD: the hope for a better tomorrow. Am J Hematol. 2025;100(Suppl 3):14\u201329.","journal-title":"Am J Hematol"},{"key":"4273_CR12","doi-asserted-by":"publisher","first-page":"1600019","DOI":"10.3389\/fimmu.2025.1600019","volume":"16","author":"A Bukauskas","year":"2025","unstructured":"Bukauskas A, Jucaitiene R, Stoskus M, Valceckiene V, Busmaite G, Slobinas A, et al. Mesenchymal stromal cells for steroid-refractory biopsy-proven grade III\u2013IV acute Graft-versus-host disease with predominant gastrointestinal involvement. Front Immunol. 2025;16:1600019.","journal-title":"Front Immunol"},{"issue":"19","key":"4273_CR13","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800\u201310.","journal-title":"N Engl J Med"},{"key":"4273_CR14","doi-asserted-by":"publisher","first-page":"954268","DOI":"10.3389\/fimmu.2022.954268","volume":"13","author":"S Fan","year":"2022","unstructured":"Fan S, Huo WX, Yang Y, Shen MZ, Mo XD. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis. Front Immunol. 2022;13:954268.","journal-title":"Front Immunol"},{"issue":"20","key":"4273_CR15","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood.2020004823","volume":"135","author":"M Jagasia","year":"2020","unstructured":"Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739\u201349.","journal-title":"Blood"},{"issue":"19","key":"4273_CR16","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/blood.2024025705","volume":"145","author":"M Gooptu","year":"2025","unstructured":"Gooptu M, Murdock HM, Soiffer RJ. How I treat AML relapse after allogeneic HSCT. Blood. 2025;145(19):2128\u201337.","journal-title":"Blood"},{"issue":"22","key":"4273_CR17","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"138","author":"C Cutler","year":"2021","unstructured":"Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138(22):2278\u201389.","journal-title":"Blood"},{"issue":"47","key":"4273_CR18","doi-asserted-by":"publisher","first-page":"16814","DOI":"10.1073\/pnas.1414189111","volume":"111","author":"A Zanin-Zhorov","year":"2014","unstructured":"Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111(47):16814\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"4273_CR19","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","volume":"127","author":"R Flynn","year":"2016","unstructured":"Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17):2144\u201354.","journal-title":"Blood"},{"issue":"437","key":"4273_CR20","doi-asserted-by":"publisher","first-page":"ra73","DOI":"10.1126\/scisignal.aad8953","volume":"9","author":"JM Weiss","year":"2016","unstructured":"Weiss JM, Chen W, Nyuydzefe MS, Trzeciak A, Flynn R, Tonra JR, et al. ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. Sci Signal. 2016;9(437):ra73.","journal-title":"Sci Signal"},{"issue":"1","key":"4273_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41467-024-44703-7","volume":"15","author":"K Maas-Bauer","year":"2024","unstructured":"Maas-Bauer K, Stell AV, Yan KL, de Vega E, Vinnakota JM, Unger S, et al. ROCK1\/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease. Nat Commun. 2024;15(1):446.","journal-title":"Nat Commun"},{"issue":"1","key":"4273_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4273_CR23","doi-asserted-by":"publisher","first-page":"1025350","DOI":"10.3389\/fimmu.2022.1025350","volume":"13","author":"AC Li","year":"2022","unstructured":"Li AC, Dong C, Tay ST, Ananthakrishnan A, Ma KS. Vedolizumab for acute gastrointestinal graft-versus-host disease: a systematic review and meta-analysis. Front Immunol. 2022;13:1025350.","journal-title":"Front Immunol"},{"issue":"6","key":"4273_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-023-01022-z","volume":"20","author":"N Kadri","year":"2023","unstructured":"Kadri N, Amu S, Iacobaeus E, Boberg E, Le Blanc K. Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cell Mol Immunol. 2023;20(6):613\u201325.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"4273_CR25","doi-asserted-by":"publisher","first-page":"e0136991","DOI":"10.1371\/journal.pone.0136991","volume":"10","author":"X Chen","year":"2015","unstructured":"Chen X, Wang C, Yin J, Xu J, Wei J, Zhang Y. Efficacy of mesenchymal stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. PLoS ONE. 2015;10(8):e0136991.","journal-title":"PLoS ONE"},{"issue":"8","key":"4273_CR26","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.bbmt.2019.04.003","volume":"25","author":"S Abedin","year":"2019","unstructured":"Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, et al. Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(8):1689\u201394.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4273_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjh.17700","volume":"195","author":"S Abedin","year":"2021","unstructured":"Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease\u2014a real-world outcomes analysis. Br J Haematol. 2021;195(3):429\u201332.","journal-title":"Br J Haematol"},{"issue":"4","key":"4273_CR28","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","volume":"3","author":"M Yeshurun","year":"2019","unstructured":"Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019;3(4):670\u201380.","journal-title":"Blood Adv"},{"issue":"8","key":"4273_CR29","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1182\/blood.2025028617","volume":"146","author":"G Socie","year":"2025","unstructured":"Socie G. Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies. Blood. 2025;146(8):926\u201337.","journal-title":"Blood"},{"issue":"12","key":"4273_CR30","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1182\/bloodadvances.2022007296","volume":"6","author":"A Etra","year":"2022","unstructured":"Etra A, Gergoudis S, Morales G, Spyrou N, Shah J, Kowalyk S, et al. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Adv. 2022;6(12):3707\u201315.","journal-title":"Blood Adv"},{"key":"4273_CR31","doi-asserted-by":"publisher","first-page":"108823","DOI":"10.1016\/j.clim.2021.108823","volume":"230","author":"A Zanin-Zhorov","year":"2021","unstructured":"Zanin-Zhorov A, Blazar BR (2021) ROCK2 a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. Clin Immunol 230:108823. https:\/\/doi.org\/10.1016\/j.clim.2021.108823","journal-title":"Clin Immunol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04273-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:22:52Z","timestamp":1788495772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04273-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":31,"alternative-id":["4273"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04273-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors has a relevant conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional ethics committee, which waived the requirement for informed consent owing to the retrospective nature of the analysis.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}